AI-Powered Pharma Companies Accelerate Exploration of Cutting-Edge Therapeutic Frontiers

　　【Pharmaceutical Network Industry DynamicsIn recent years, an increasing number of pharmaceutical companies, in order to develop innovative drugs more quickly, efficiently, and with lower costs, are actively collaborating with AI drug discovery companies and AI platforms to jointly advance the continuous innovation and development in research areas such as drug target discovery, rational drug design, and drug repurposing.
 

On September 12, biotechnology company Exelixis and Insilico Medicine jointly announced that they had signed an exclusive licensing agreement, under which Exelixis will obtain global development and commercialization rights for ISM3091 from Insilico Medicine. ISM3091 is a potential best-in-class small molecule inhibitor targeting the synthetic lethal target USP1 in BRCA-mutated tumors.
 

According to the terms of the agreement, Insilico Medicine will grant Exelixis an exclusive global license for the development and commercialization of ISM3091 and other compounds targeting USP1, and receive an upfront payment of $80 million in the third quarter of 2023. In addition, Insilico Medicine is also eligible to receive milestone payments based on subsequent development, commercialization, and sales, as well as tiered royalties on future net product sales.
 

The industry believes that the achievement of this cooperation marks continuous innovation and collaboration in the fields of artificial intelligence and biotechnology, providing new opportunities and prospects for research and development in the field of cancer treatment. In the future, it is also expected to bring more innovative treatment options for patients with BRCA-mutated tumors.
 

Public information shows that Insilico Medicine is a biopharmaceutical technology company driven by generative artificial intelligence. In recent years, it has reached new drug development collaborations with many pharmaceutical companies. For instance, in August this year, Insilico Medicine announced that ISM8207, a candidate drug for treating advanced malignant tumors co-developed with Fosun Pharma, had received tacit approval for clinical trials from the National Medical Products Administration (NMPA) and is expected to commence Phase I clinical trials in China once conditions are met. This marks the first clinical milestone achieved since the strategic cooperation between Insilico Medicine and Fosun Pharma.
 

In fact, at present, the application of AI technology in the pharmaceutical field has become a very important trend, shaping the development of the entire pharmaceutical and biotechnology industry. In addition to Insilico Medicine, XtalPi has also been reaching new drug discovery collaborations with large pharma and Biotech companies both in China and abroad this year, driving multiple cancer drug R&D projects and AI-empowered process optimization projects simultaneously through AI algorithms.
 

On September 4, XtalPi announced a collaboration with Parthenon Therapeutics, a company focused on remodeling the tumor microenvironment, to jointly develop antibody drugs for solid tumors. On May 31, XtalPi announced a collaboration agreement with Eli Lilly for AI-driven small molecule drug discovery, with upfront and milestone payments totaling up to $250 million.
 

　　……
 

Overall, against the backdrop of the continuous integration of AI and the pharmaceutical industry, numerous pharmaceutical companies are accelerating their exploration into frontier areas that have not yet been ventured into by any enterprises globally, such as small molecule crystal structure prediction and de novo drug design. It is reported that in China, AI-driven drug research and development achieved significant breakthroughs in 2022. As of 2022, among 80 Chinese AI pharmaceutical companies, 14 have successfully advanced their pipelines to the clinical stage, with most being in Phase I clinical trials. Notably, Insilico Medicine’s first fully AI-based pipeline, ISM001-005, has entered Phase I clinical trials and completed dosing in the first group of healthy subjects.
 

In the future, it is expected that with the support of AI, pharmaceutical companies in China will be able to process and analyze large amounts of biochemical information more quickly, screen out suitable compounds, and design and optimize drug molecular structures. While achieving the goal of reducing costs and increasing efficiency, the competitiveness of China's pharmaceutical enterprises will continue to improve.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.